Abstract
Daclizumab (Zenapax®, Roche) is a humanized murine monoclonal IgG1k antibody specifically binding to the high affinity interleukin-2 (IL-2R) expressed on human lymphocytes. At the end of 2009 its production was discontinued and the supply was announced to last up to 2011. However, some trials are exploring new indications, and long-term observations are still collecting data, which are relevant for safety evaluation of chronic exposures to this class of biomedicines.
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Daclizumab (Zenapax®) BLA 97-0736 FDA Clinical Review 1997
Daclizumab (Zenapax®) BLA 97-0736 FDA Safety Review 1997
Carswell C, Plosker GL, Wagstaff AJ (2001) Daclizumab. A review of its use in the management of organ transplantation. BioDrugs 15:745–773
Zenapax® (Daclizumab) Label, Hofmann-La Roche, US 2005
Zenapax® (Daclizumab) Product Monograph, Hoffmann-La Roche, Canada 2007
Daclizumab (Zenapax®) EPAR WC50007604 Product Information Annex I, EMEA 2008
Binder M, Vögtle FN, Michelfelder S et al (2007) Identification of their epitope reveals the structural basis for the mechanism of action of the immunosuppressive antibodies Basiliximab and Daclizumab. Cancer Res 67:3518–3523
Bielkova B (2012) Daclizumab therapy for Multiple Sclerosis. Neurotherapeutics. doi:10.1007/s13311-012-0147-4
Gold R, Giovannoni G, Selmaj K et al (2013) Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomized, double-blind placebo-controlled trial. Lancet. doi:10.1016/S0140-6736(12)62190-4
Daclizumab (Zenapax®) BLA 97-0736 FDA Non-clinical pharmacology and toxicology review 1997
FDA Safety information letter. Medwatch, August 2003
Birgerson LE (2009) Important drug information. Roche, US Medical Affairs
Emre S, Gondolesi G, Polat K et al (2001) Use of daclizumab as initial immunosuppression in liver transplant recipients with impaired renal function. Liver Transpl 7:220–225
Yoshida EM, Marotta PJ, Greig PD et al (2005) Evaluation of renal function in liver transplant recipients receiving daclizumab (Zenapax), Mycophenolate Mofetil regimen: a multicenter randomized clinical trial. Liver Transpl 9:1064–1072
Otero A, Varo E, Ortiz de Urbina J et al (2009) A prospective randomized open study in liver transplant recipients: Daclizumab, Mycophenolate Mofetil, and Tacrolimus versus Tacrolimus and Steroids. Liver Transpl 15:1542–1552
Neumann U, Samuel D, Trunečka P et al (2012) A randomized multicenter study comparing a Tacrolimus-based protocol with and without Steroids in HCV-positive liver allograft recipients. J Transpl. doi:10.1155/2012/894215
Klintmalm GB, Davis GL, Teperman L et al (2011) A randomized, multicenter study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C. Liver Transpl 17:1394–1403
Chin C, Pittson S, Luikart H et al (2005) Induction therapy for pediatric heart and adult transplantation: comparison between OKT3 and daclizumab. Transplantation 80:477–481
Coehlo T, Tredger M, Dhawan A et al (2012) Current status of immunosuppressive agents for solid organ transplantation in children. Ped. Transpl 16:106–122
Nussenblatt RB, Peterson JS, Foster S et al (2005) Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis. Ophthalmology 112:764–770
Larson T, Nussenblatt RB and Nida Sen H (2011) Emerging drugs for uveitis. Expert Opin Emerg Drugs 16:309–322
Yeh S, Wroblewski K, Buggage R et al (2008) High-dose humanized anti-IL-2 receptor alpha antibody (daclizumab) for the treatment of active, noninfectious uveitis. J Autoimmun 31:91–97
Pasadhika S, Suhler E, Cunningham ET (2012) Biologic therapy for posterior uveitis and panuveitis. Retina Today 4:74–79
Wroblewski K, Nida Sen H, Yeh S et al (2011) Long-term daclizumab therapy for the treatment of noninfectious ocular inflammatory diseases. Can J Ophthalmol 46:322328
Rojas MA, Carlson NG, Miller TL et al (2009) Long-term daclizumab therapy in relapsing-remitting multiple sclerosis. Ther Adv Neurol Disord 2:291–297
Shippling S, Martin R (2008) Spotlight on anti-CD25: Daclizumab in MS. Intern MS J 15:94–98
Martin R (2012) Anti-CD25 (daclizumab) monoclonal antibody therapy in relapsing-remitting multiple sclerosis. Clin Immunol 142:9–14
Giovannoni G, Gold R, Selmaj K et al (2011) A randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of daclizumab HYP monotherapy in relapsing-remitting multiple sclerosis: primary results of the SELECT trial. Multiple Sclerosis Journal ,Ectrims, Amsterdam ; 17: S507–S524
Giovannoni G, Gold R, Selmaj K et al (2012) Primary results of the SELECTION trial of daclizumab HYP in relapsing multiple sclerosis. Ectrims, Lyon
Liu J, Wang L, Zhan SY et al (2012) Daclizumab for relapsing remitting multiple sclerosis (review)- The Cochrane Library, issue 4 (www.thecochranelibrary.com)
Jiang W, Chai NR, Maric D et al (2011) Unexpected role for granzyme K in CD56bright NK cell-mediate immunoregulation of multiple sclerosis. J Immunol 187:781–790
Perry JSA, Han S, Xu Q et al (2012) Inhibition of LTi cell development by CD25 blockade is associated with decreased intrathecal inflammation in multiple sclerosis. Sci Transl Med 4:145ra106 doi: 10.1126/scitranslmed.3004140
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2014 Springer-Verlag Italia
About this chapter
Cite this chapter
Tridente, G. (2014). Daclizumab. In: Adverse Events with Biomedicines. Springer, Milano. https://doi.org/10.1007/978-88-470-5313-7_16
Download citation
DOI: https://doi.org/10.1007/978-88-470-5313-7_16
Published:
Publisher Name: Springer, Milano
Print ISBN: 978-88-470-5312-0
Online ISBN: 978-88-470-5313-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)